Chemomab Therapeutics Q2 EPS $(0.24) Misses $(0.15) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 33.33 percent increase over losses of $(0.36) per share from the same period last year.